Cargando…

S100A8/A9 in Inflammation

S100A8 and S100A9 (also known as MRP8 and MRP14, respectively) are Ca(2+) binding proteins belonging to the S100 family. They often exist in the form of heterodimer, while homodimer exists very little because of the stability. S100A8/A9 is constitutively expressed in neutrophils and monocytes as a C...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Siwen, Song, Rui, Wang, Ziyi, Jing, Zhaocheng, Wang, Shaoxiong, Ma, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004386/
https://www.ncbi.nlm.nih.gov/pubmed/29942307
http://dx.doi.org/10.3389/fimmu.2018.01298
_version_ 1783332511659589632
author Wang, Siwen
Song, Rui
Wang, Ziyi
Jing, Zhaocheng
Wang, Shaoxiong
Ma, Jian
author_facet Wang, Siwen
Song, Rui
Wang, Ziyi
Jing, Zhaocheng
Wang, Shaoxiong
Ma, Jian
author_sort Wang, Siwen
collection PubMed
description S100A8 and S100A9 (also known as MRP8 and MRP14, respectively) are Ca(2+) binding proteins belonging to the S100 family. They often exist in the form of heterodimer, while homodimer exists very little because of the stability. S100A8/A9 is constitutively expressed in neutrophils and monocytes as a Ca(2+) sensor, participating in cytoskeleton rearrangement and arachidonic acid metabolism. During inflammation, S100A8/A9 is released actively and exerts a critical role in modulating the inflammatory response by stimulating leukocyte recruitment and inducing cytokine secretion. S100A8/A9 serves as a candidate biomarker for diagnosis and follow-up as well as a predictive indicator of therapeutic responses to inflammation-associated diseases. As blockade of S100A8/A9 activity using small-molecule inhibitors or antibodies improves pathological conditions in murine models, the heterodimer has potential as a therapeutic target. In this review, we provide a comprehensive and detailed overview of the distribution and biological functions of S100A8/A9 and highlight its application as a diagnostic and therapeutic target in inflammation-associated diseases.
format Online
Article
Text
id pubmed-6004386
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60043862018-06-25 S100A8/A9 in Inflammation Wang, Siwen Song, Rui Wang, Ziyi Jing, Zhaocheng Wang, Shaoxiong Ma, Jian Front Immunol Immunology S100A8 and S100A9 (also known as MRP8 and MRP14, respectively) are Ca(2+) binding proteins belonging to the S100 family. They often exist in the form of heterodimer, while homodimer exists very little because of the stability. S100A8/A9 is constitutively expressed in neutrophils and monocytes as a Ca(2+) sensor, participating in cytoskeleton rearrangement and arachidonic acid metabolism. During inflammation, S100A8/A9 is released actively and exerts a critical role in modulating the inflammatory response by stimulating leukocyte recruitment and inducing cytokine secretion. S100A8/A9 serves as a candidate biomarker for diagnosis and follow-up as well as a predictive indicator of therapeutic responses to inflammation-associated diseases. As blockade of S100A8/A9 activity using small-molecule inhibitors or antibodies improves pathological conditions in murine models, the heterodimer has potential as a therapeutic target. In this review, we provide a comprehensive and detailed overview of the distribution and biological functions of S100A8/A9 and highlight its application as a diagnostic and therapeutic target in inflammation-associated diseases. Frontiers Media S.A. 2018-06-11 /pmc/articles/PMC6004386/ /pubmed/29942307 http://dx.doi.org/10.3389/fimmu.2018.01298 Text en Copyright © 2018 Wang, Song, Wang, Jing, Wang and Ma. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Siwen
Song, Rui
Wang, Ziyi
Jing, Zhaocheng
Wang, Shaoxiong
Ma, Jian
S100A8/A9 in Inflammation
title S100A8/A9 in Inflammation
title_full S100A8/A9 in Inflammation
title_fullStr S100A8/A9 in Inflammation
title_full_unstemmed S100A8/A9 in Inflammation
title_short S100A8/A9 in Inflammation
title_sort s100a8/a9 in inflammation
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004386/
https://www.ncbi.nlm.nih.gov/pubmed/29942307
http://dx.doi.org/10.3389/fimmu.2018.01298
work_keys_str_mv AT wangsiwen s100a8a9ininflammation
AT songrui s100a8a9ininflammation
AT wangziyi s100a8a9ininflammation
AT jingzhaocheng s100a8a9ininflammation
AT wangshaoxiong s100a8a9ininflammation
AT majian s100a8a9ininflammation